Centinel Spine announced the 100th completed procedure in the U.S. with its prodisc® C Vivo Cervical Total Disc Replacement (TDR). This milestone was achieved after the company announced the first U.S. implantation of the prodisc C Vivo in September 2022.
The prodisc C Vivo system has been in clinical use internationally since 2009, and is reportedly one of the most frequently implanted TDR devices in the world. The device features keel-less fixation and combines an anatomically-designed superior endplate with lateral spikes to optimize fit and provide immediate fixation.
Centinel Spine’s cervical TDR portfolio includes four devices approved by FDA for 1-level indications, offering a broad spectrum of solutions to address surgeon preference and individual patient anatomy.
Centinel Spine announced the 100th completed procedure in the U.S. with its prodisc® C Vivo Cervical Total Disc Replacement (TDR). This milestone was achieved after the company announced the first U.S. implantation of the prodisc C Vivo in September 2022.
The prodisc C Vivo system has been in clinical use internationally since 2009, and is...
Centinel Spine announced the 100th completed procedure in the U.S. with its prodisc® C Vivo Cervical Total Disc Replacement (TDR). This milestone was achieved after the company announced the first U.S. implantation of the prodisc C Vivo in September 2022.
The prodisc C Vivo system has been in clinical use internationally since 2009, and is reportedly one of the most frequently implanted TDR devices in the world. The device features keel-less fixation and combines an anatomically-designed superior endplate with lateral spikes to optimize fit and provide immediate fixation.
Centinel Spine’s cervical TDR portfolio includes four devices approved by FDA for 1-level indications, offering a broad spectrum of solutions to address surgeon preference and individual patient anatomy.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
